Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in XXXX @entity189 .

@entity1 @entity5 @entity189 @entity982 @entity3214 @entity3 @entity1349 @entity71856
UNASSIGNED: Chromosome 14 open reading frame 166 ( @entity71856 ) contributes to regulation of centrosome architecture, transcription initiation, and RNA elongation and processing. However, the role of @entity71856 in @entity1 @entity5 remains unclear. This study aimed to investigate the expression and clinicopathological significance of @entity71856 in @entity189 ( @entity189 ). Real-time PCR and Western blotting analyses were employed to examine @entity71856 expression in immortalized primary nasopharyngeal epithelial cells (NP69), six @entity189 cell lines, three paired @entity5 samples and the adjacent noncancerous tissues from the same @entity1 , and three additional @entity5 samples. Immunohistochemistry was performed to examine @entity71856 protein expression in archived @entity982 -embedded @entity5 samples from 109 @entity1 with clinicopathologically confirmed @entity189 . The association of @entity71856 expression with clinicopathological features and survival outcomes was assessed. @entity71856 messenger RNA and protein expression were upregulated in @entity189 cell lines and @entity1 @entity5 tissues compared to NP69 cells and noncancerous tissue samples, respectively. Immunohistochemical analyses revealed 104/109 (95.4  %) of the @entity189 tissue samples expressed @entity71856 . High expression of @entity71856 (cutoff score >6) was significantly associated with gender (P   =   0.016), clinical stage (P   =   0.010), T classification (P   =   0.013), N classification (P   =   0.029), distant @entity3 (P   <   0.001), vital status (P   =   0.001), and treatment method (P   =   0.028; chi-square test). High @entity71856 expression was associated with significantly shorter @entity1349 ( @entity1349 ) and disease-free survival (DFS) than low @entity71856 expression. Multivariate analysis revealed @entity71856 was an independent prognostic indicator of @entity1349 and DFS in all @entity1 (P   =   0.046, P   =   0.006) and was associated with poor @entity1349 and DFS in the subgroups with advanced clinical stage (P   =   0.037, P   =   0.001), lymph node @entity3 (P   =   0.001, P   <   0.001), and @entity3214 (P   =   0.005, P   =   0.001), respectively. @entity71856 is overexpressed and may represent a novel prognostic factor in @entity189 .
